Pyogenic Granuloma

1. Clinical Overview

Summary

Pyogenic granuloma (PG) is a common, benign, acquired vascular tumour that presents as a rapidly growing, friable, red-to-purple nodule with a propensity to bleed profusely with minimal trauma. [1] Despite its historical name, pyogenic granuloma is a complete misnomer — it is neither pyogenic (no infectious or purulent aetiology) nor a true granuloma (no granulomatous inflammation). The scientifically accurate term is lobular capillary haemangioma, reflecting its histopathological architecture. [2]

Pyogenic granuloma affects all ages but shows peak incidence in children and young adults, with a second peak in pregnant women (where it is termed granuloma gravidarum or pregnancy tumour). [3] The condition typically arises at sites of minor trauma and favours acral locations — particularly the fingers (especially periungual), face, lips, and oral mucosa. The gingiva is the most common intraoral site, especially during pregnancy. [4]

The cardinal clinical feature is a dome-shaped, glistening, friable nodule that bleeds disproportionately to the degree of trauma, often with a characteristic collarette of scale at the base. While the lesion appears alarming due to rapid growth and bleeding, it is entirely benign. However, the critical diagnostic challenge is distinguishing pyogenic granuloma from amelanotic melanoma, which can present almost identically. [5] This necessitates histopathological confirmation in all cases.

Management is straightforward: curettage and cauterisation remain first-line, with histological examination of all specimens essential. [6] Recurrence rates range from 10-40% depending on adequacy of initial treatment, with the rare complication of satellitosis (multiple recurrent lesions surrounding the scar) occurring in inadequately treated cases. [7] Pregnancy-associated lesions often regress spontaneously post-partum, permitting conservative management if the lesion is not symptomatic. [8]

---

Key Facts

• Nomenclature: Lobular capillary haemangioma (NOT pyogenic or granuloma)
• Pathology: Benign vascular proliferation; lobular architecture
• Appearance: Bright red, friable, pedunculated or sessile nodule; collarette of scale
• Hallmark: Profuse bleeding with minimal trauma
• Sites: Fingers (periungual), face, lips, oral mucosa (especially gingiva)
• Triggers: Minor trauma (most cases), pregnancy, medications (retinoids, EGFRi, TKIs)
• Treatment: Curettage + cautery; always send for histology
• Critical DDx: Amelanotic melanoma — never assume benign without histology

---

Clinical Pearls

"Triple Misnomer": Not pyogenic (no infection), not a granuloma (no granulomatous inflammation), and not a tumour in the malignant sense — it's a benign vascular proliferation.

"Bleeds Like Crazy": The hallmark is profuse, disproportionate bleeding from minor trauma. Parents often present acutely after a child's lesion bleeds heavily from a minor knock.

"Collar Sign": A collarette (ring) of epithelial scale at the base is a classic finding and helps differentiate from amelanotic melanoma.

"Always Histology": Never assume a rapidly growing vascular nodule is benign. Amelanotic melanoma can be clinically indistinguishable. Histology is mandatory.

"Pregnancy = Gingiva": In pregnant women, think gingiva first — granuloma gravidarum typically appears in the second or third trimester and often regresses post-partum.

"Satellitosis After Surgery": Incomplete excision or inadequate cauterisation can lead to satellitosis — multiple recurrent PG lesions around the scar. Ensure thorough cauterisation of the base.

---

2. Epidemiology

Incidence and Prevalence

Pyogenic granuloma is a very common lesion encountered in dermatology, primary care, and surgical clinics. It accounts for approximately 0.5% of all skin nodules in paediatric populations. [9] Exact prevalence data are limited because many lesions are excised without formal epidemiological capture, but it is considered one of the most frequent benign vascular tumours of the skin and mucosa. [1]

Oral pyogenic granuloma represents approximately 26-32% of all reactive gingival lesions, making it the second most common reactive oral lesion after fibrous hyperplasia. [10]

Demographics

Risk Factors

---

3. Aetiology & Pathophysiology

Historical Context

The term "pyogenic granuloma" was coined in the early 20th century under the mistaken belief that the lesion represented an exuberant granulomatous response to bacterial infection. This is now known to be incorrect — there is no infectious aetiology and no granulomatous inflammation. The accurate histopathological term is lobular capillary haemangioma. [2]

Aetiological Mechanisms

The precise aetiology remains incompletely understood, but the current consensus is that pyogenic granuloma represents an exaggerated proliferative vascular response to tissue injury, hormonal stimulation, or angiogenic dysregulation. [1,2]

Trauma-Induced Angiogenesis

Most cases (60-70%) follow minor trauma — a cut, insect bite, or chronic friction. The proposed mechanism involves:

1. Vascular injury → disruption of endothelial integrity
2. Inflammatory cascade → release of cytokines (TNF-α, IL-1, IL-6)
3. Angiogenic upregulation → increased VEGF, bFGF, and TGF-β expression
4. Abnormal vascular proliferation → lobular capillary architecture [14]

Hormonal Modulation (Pregnancy)

Pregnancy-associated pyogenic granuloma (granuloma gravidarum) is driven by:

• Oestrogen and progesterone → upregulation of VEGF and angiogenic receptors (VEGFR-2, Tie-2) [8]
• Increased vascular permeability → oedema and rapid lesion expansion
• Placental growth factor (PlGF) → additional angiogenic stimulus [8]
• This explains why lesions often regress post-partum when hormonal levels normalise. [8]

Medication-Induced Mechanisms

Drug-induced pyogenic granuloma is well-described with:

• Retinoids (isotretinoin, acitretin): Altered keratinocyte differentiation → impaired re-epithelialisation → vascular overgrowth [11]
• EGFR inhibitors (cetuximab, erlotinib): Disrupted epidermal barrier → inflammation → angiogenic response [12]
• TKIs (ibrutinib, sunitinib): Off-target effects on VEGF signalling → abnormal angiogenesis [12]
• Antiretrovirals (indinavir, ritonavir): Metabolic effects → endothelial dysfunction and vascular proliferation [13]

Molecular Pathophysiology

Recent advances have identified somatic mutations in vascular anomalies, but pyogenic granuloma has not consistently demonstrated specific driver mutations unlike other vascular tumours (e.g., infantile haemangioma with GLUT1 expression, or vascular malformations with PIK3CA/GNAQ mutations). [15]

Instead, pyogenic granuloma appears to represent a reactive, polyclonal vascular proliferation driven by:

• Overexpression of angiogenic factors: VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), TGF-β (transforming growth factor-beta) [14]
• Endothelial cell proliferation: Marked increase in proliferating endothelial cells (Ki-67 positive) [14]
• Matrix remodelling: Upregulation of matrix metalloproteinases (MMPs) → tissue invasion and rapid growth [14]

The lobular architecture on histology reflects aberrant capillary proliferation organised into discrete lobules separated by fibrous septa — the histological hallmark of the lesion. [2]

Genetic and Familial Factors

Pyogenic granuloma is not hereditary. There are no known familial syndromes or genetic predispositions. All cases are acquired. [2]

---

4. Clinical Presentation

Typical Appearance

Pyogenic granuloma presents as a solitary, dome-shaped or pedunculated nodule with characteristic features:

Anatomical Distribution

Clinical Variants

1. Granuloma Gravidarum (Pregnancy Tumour)

• Occurs in ~5% of pregnancies, typically 2nd or 3rd trimester [8]
• Gingival location in > 90% of cases (due to hormonal gingivitis and vascular engorgement) [8]
• Often regresses spontaneously post-partum (50-70% of cases) [8]
• Can recur in subsequent pregnancies
• Management: Conservative if asymptomatic; excision if bleeding, pain, or functional impairment

2. Periungual/Subungual Pyogenic Granuloma

• Common in children and young adults following nail trauma or chronic paronychia [1]
• Can cause nail dystrophy or onycholysis
• Higher recurrence rate due to difficulty achieving complete excision without nail matrix damage

3. Multiple/Eruptive Pyogenic Granulomas

• Rare variant: sudden onset of multiple lesions (5-100+) [17]
• Associations: Retinoid therapy, EGFR inhibitors, indinavir, burn injuries, widespread trauma [11,12,17]
• Satellitosis: Multiple recurrent lesions around a scar from previous excision — indicates incomplete treatment [7]

4. Intraoral Pyogenic Granuloma

• Gingiva (75% of oral cases): interdental papilla most common [10]
• Buccal mucosa, tongue, palate (25%)
• Risk factors: Poor oral hygiene, dental trauma, pregnancy, drugs [10]

Symptoms

Natural History

• Rapid growth phase: Typically grows rapidly over 2-4 weeks to reach 5-10 mm, then plateaus [2]
• Spontaneous regression: Rare (less than 5%) except in pregnancy-associated cases (50-70% post-partum regression) [8]
• Bleeding episodes: Recurrent bleeding is common due to friable surface; can be socially and functionally disabling
• Secondary infection: Occasional; presents with increased pain, purulent discharge, surrounding erythema

---

5. Differential Diagnosis

The most critical differential is amelanotic melanoma, which can be clinically indistinguishable from pyogenic granuloma. All rapidly growing vascular nodules require histological confirmation. [5]

Key Differentials

Red Flags for Melanoma

🚩 Age > 50 years with new vascular nodule
🚩 Irregular pigmentation at edges or within lesion
🚩 Firm consistency (PG is typically soft/friable)
🚩 Slow growth (melanoma usually weeks-months; PG days-weeks)
🚩 Ulceration without trauma
🚩 Enlarging pigmented lesion preceding the nodule

GOLDEN RULE: If in doubt, excise and send for histology. Never assume benign.

---

6. Investigations

Clinical Diagnosis

Pyogenic granuloma is primarily a clinical diagnosis based on:

1. Characteristic appearance: Friable, red, pedunculated/sessile nodule with collarette
2. History of trauma or pregnancy
3. Profuse bleeding with minor trauma
4. Rapid growth over days to weeks

However, histological confirmation is mandatory in all cases to exclude malignancy (especially amelanotic melanoma). [5]

Dermoscopy

Dermoscopy can aid diagnosis but cannot replace histology. [18]

Typical dermoscopic features of pyogenic granuloma:

• Red lacunae (vascular spaces) — resembles "red grapes"
• White rail lines (fibrous septa between lobules)
• White collarette (epidermal ring at base)
• Central ulceration or crust
• Absence of pigment network (helps exclude pigmented lesions)

Pitfalls: Amelanotic melanoma can show similar vascularisation patterns. Dermoscopy aids but does not exclude malignancy. [18]

Histopathology (Gold Standard)

Indications: ALL cases — histology is mandatory to confirm diagnosis and exclude melanoma. [5,6]

Specimen: Curettage or excision specimen; formalin-fixed

Histological features [2]:

• Lobular architecture: Discrete lobules of capillaries separated by fibrous septa (hallmark)
• Capillary proliferation: Plump endothelial cells forming capillary lumens
• Oedematous stroma: Myxoid or oedematous connective tissue
• Ulceration: Frequent; overlying epidermis often ulcerated due to trauma
• Neutrophilic infiltrate: Common on surface; may see microabscesses (originally mistaken for infection)
• Collarette of epithelium: Epidermal hyperplasia at periphery forming a "collar"
• No granulomatous inflammation: Confirms it is NOT a true granuloma
• No malignant features: Absence of atypia, mitoses, or infiltrative growth

Immunohistochemistry (if diagnosis uncertain):

• Vascular markers: CD31+, CD34+, ERG+ (confirms vascular nature)
• GLUT1 negative (differentiates from infantile haemangioma, which is GLUT1+)
• S100, Melan-A, HMB-45 negative (excludes melanoma)

Imaging

Not routinely required. Imaging is reserved for rare scenarios:

• MRI: For deep or visceral lesions (e.g., intraoral lesions with suspected bone involvement)
• Ultrasound: Can demonstrate hypervascularity but rarely needed
• CT: For nasal/sinus lesions if bone erosion suspected

In pregnancy-associated nasal lesions (granuloma gravidarum of the nose), MRI is superior to CT for soft tissue characterisation and avoids ionising radiation. [16]

---

7. Management

General Principles

1. Histological confirmation is mandatory — send all specimens for histopathology
2. Curettage + cautery is first-line for most lesions
3. Adequate cauterisation of the base reduces recurrence risk
4. Pregnancy-associated lesions can be managed conservatively if asymptomatic (many regress post-partum)
5. Oral lesions require dental referral for optimisation of oral hygiene and removal of local irritants

---

First-Line Treatment: Curettage and Cauterisation [6]

Indications: Most pyogenic granulomas (cutaneous and mucosal)

Procedure:

1. Local anaesthesia: Lidocaine 1-2% with adrenaline (for vasoconstriction and haemostasis)
2. Curettage: Use a dermal curette to scoop out the lesion from the base
3. Cauterisation: Apply cautery (electrocautery or chemical cautery) to the base to destroy residual tissue and achieve haemostasis
   • Electrocautery: Hyfrecation or diathermy
   • Chemical cautery: Aluminium chloride 35%, silver nitrate, or ferric subsulfate
4. Send specimen for histology: Mandatory — never discard
5. Dressing: Apply pressure, then non-adherent dressing

Advantages:

• Quick, simple, office-based procedure
• Low cost
• Good cosmetic outcome
• Low recurrence if adequate cauterisation (10-15%) [6]

Disadvantages:

• Recurrence if inadequate cauterisation (30-40% if base not treated) [7]
• Satellitosis risk (multiple recurrences around scar) if incomplete [7]

Recurrence Prevention:

• Thorough cauterisation of the base is critical
• Some advocate cauterising slightly beyond the visible base to destroy feeder vessels [6]

---

Alternative Surgical Options

1. Surgical Excision with Primary Closure

Indications:

• Diagnostic uncertainty (concern for melanoma)
• Large lesions (> 1 cm)
• Periungual lesions requiring nail matrix preservation
• Recurrent lesions despite curettage

Technique:

• Elliptical excision with 2-3 mm margin
• Primary closure with sutures
• Send for histology

Advantages:

• Lower recurrence rate (less than 5%) [6]
• Provides intact specimen for histology (better for atypical lesions)

Disadvantages:

• Scar formation
• More time-consuming
• Requires suturing skills

2. Shave Excision + Cautery

Indications: Pedunculated lesions

Technique:

• Shave lesion at base with scalpel
• Cauterise base
• Send for histology

Advantages: Quick, simple, good cosmesis for pedunculated lesions

Disadvantages: Higher recurrence than full excision

---

Non-Surgical Treatment Options

1. Laser Therapy

Pulsed Dye Laser (PDL) [19]:

• Mechanism: Selective photothermolysis of haemoglobin → vascular destruction
• Technique: 585-595 nm wavelength, 7-10 mm spot size, multiple sessions (2-4 typically)
• Advantages: Excellent cosmesis, no scarring, good for facial/paediatric lesions
• Disadvantages: Multiple sessions required, expensive, availability limited, recurrence 10-20%

CO₂ Laser [19]:

• Mechanism: Vaporisation of tissue
• Advantages: Precise tissue removal, good haemostasis
• Disadvantages: Scarring risk, requires local anaesthesia

Indications for laser: Facial lesions (especially children), multiple lesions, patient preference for scar-free outcome

2. Cryotherapy

Technique: Liquid nitrogen application (freeze-thaw cycles)

Efficacy: Variable; high recurrence rate (40-50%) [6]

Indications: Small, superficial lesions; not recommended as first-line

Disadvantages: Pain, blistering, dyspigmentation, high recurrence

3. Topical Beta-Blockers (Timolol Maleate 0.5%)

Mechanism: Vasoconstriction, reduced VEGF expression, apoptosis of capillary endothelial cells [20]

Technique: Apply timolol 0.5% gel or solution twice daily to lesion

Efficacy: Variable — complete response in 30-40%, partial in 30%, no response in 30% [20]

Indications:

• Small lesions (less than 5 mm)
• Paediatric patients (avoid invasive surgery)
• Facial/periorbital lesions (avoid scarring)
• Delicate areas (lips, gums, genitalia)

Advantages: Non-invasive, painless, no scarring

Disadvantages: Variable efficacy, requires compliance (weeks to months), not effective for all lesions

Contraindications: Bradycardia, heart block, asthma, hypotension

Evidence: Small case series show promise but efficacy inferior to surgery. [20]

4. Sclerotherapy

Agents: Sodium tetradecyl sulfate, polidocanol

Technique: Intralesional injection of sclerosant

Efficacy: Limited evidence; small case series

Disadvantages: Pain, ulceration risk, recurrence

Indications: Reserved for inoperable lesions or patient refusal of surgery

5. Silver Nitrate Cautery

Technique: Topical application of silver nitrate sticks after local anaesthesia

Efficacy: Poor — high recurrence (> 50%) [6]

Indications: Very superficial, small lesions; not recommended as monotherapy

---

Management in Special Populations

Pregnancy (Granuloma Gravidarum) [8]

Conservative Management (Preferred):

• Observation if asymptomatic (lesion often regresses post-partum in 50-70%)
• Oral hygiene optimisation for gingival lesions
• Reassurance

Surgical Management (Indications):

• Persistent bleeding
• Functional impairment (eating, speaking)
• Pain or secondary infection
• Patient distress

Timing:

• Can defer until post-partum if possible (reduces recurrence)
• If intervention required during pregnancy: curettage + cautery safe (local anaesthesia only)

Post-partum: Re-assess at 6-8 weeks; if persistent, proceed to definitive treatment

Paediatric Patients [9]

Considerations:

• Periungual lesions common (trauma-related)
• Psychological impact of bleeding
• Prefer minimally invasive options if possible (topical timolol, laser)
• If surgery required: ensure adequate analgesia/anxiolysis; consider general anaesthesia for young children or extensive lesions

Oral Lesions [10]

Pre-treatment:

• Dental assessment: remove local irritants (calculus, sharp teeth, ill-fitting dentures)
• Improve oral hygiene

Treatment: Surgical excision or curettage + cautery by dentist/oral surgeon

Post-treatment: Maintain excellent oral hygiene to prevent recurrence

---

Management Algorithm

┌────────────────────────────────────────────────────────────────────┐
│                  PYOGENIC GRANULOMA MANAGEMENT                     │
├────────────────────────────────────────────────────────────────────┤
│                                                                    │
│  STEP 1: CLINICAL DIAGNOSIS                                        │
│  • Friable, red nodule with rapid growth and profuse bleeding     │
│  • History of trauma or pregnancy                                 │
│  • Dermoscopy: red lacunae, white rail lines, collarette          │
│                                                                    │
│  ⚠ IF DIAGNOSTIC DOUBT (concern for melanoma) → EXCISION BIOPSY  │
│                                                                    │
├────────────────────────────────────────────────────────────────────┤
│  STEP 2: ASSESS CONTEXT                                            │
│                                                                    │
│  PREGNANCY-ASSOCIATED (GRANULOMA GRAVIDARUM)?                      │
│  ├─ YES:                                                           │
│  │  ├─ Asymptomatic → Conservative (often regresses post-partum)  │
│  │  └─ Symptomatic (bleeding, pain, function) → Curettage+cautery │
│  └─ NO: Proceed to Step 3                                         │
│                                                                    │
├────────────────────────────────────────────────────────────────────┤
│  STEP 3: FIRST-LINE TREATMENT                                      │
│                                                                    │
│  **CURETTAGE + CAUTERY** (under local anaesthesia)                 │
│  • Curette lesion from base                                       │
│  • Cauterise base thoroughly (electrocautery or chemical)         │
│  • ✅ SEND FOR HISTOLOGY (mandatory)                              │
│                                                                    │
│  Expected outcome: Cure in 85-90%, recurrence 10-15%               │
│                                                                    │
├────────────────────────────────────────────────────────────────────┤
│  STEP 4: ALTERNATIVE OPTIONS (if first-line unsuitable)           │
│                                                                    │
│  • EXCISION: Diagnostic uncertainty, large lesions, recurrent PG  │
│  • LASER (PDL): Facial lesions, paediatric, cosmesis priority     │
│  • TIMOLOL 0.5%: Small lesions, paediatric, non-invasive option   │
│  • CRYOTHERAPY: Rarely used (high recurrence)                     │
│                                                                    │
├────────────────────────────────────────────────────────────────────┤
│  STEP 5: RECURRENCE MANAGEMENT                                     │
│                                                                    │
│  SINGLE RECURRENCE:                                                │
│  • Repeat curettage + cautery (ensure thorough base treatment)    │
│  • Consider excision for definitive treatment                     │
│                                                                    │
│  SATELLITOSIS (multiple recurrences around scar):                  │
│  • Excision of entire scar + surrounding lesions with margin      │
│  • Consider referral to dermatology/plastics                      │
│                                                                    │
└────────────────────────────────────────────────────────────────────┘

---

8. Complications

Complications of Pyogenic Granuloma (Untreated)

Complications of Treatment

---

9. Prognosis & Outcomes

With Treatment

Curettage + Cautery [6]:

• Cure rate: 85-90%
• Recurrence: 10-15% (if adequate cauterisation)
• Recurrence: 30-40% (if inadequate cauterisation or base not treated)
• Time to recurrence: Typically within 3-6 months

Excision [6]:

• Cure rate: 95-98%
• Recurrence: less than 5%

Laser (PDL) [19]:

• Cure rate: 80-85%
• Recurrence: 10-20%
• Sessions required: 2-4 on average

Timolol [20]:

• Complete response: 30-40%
• Partial response: 30%
• No response: 30%
• Time to response: 4-12 weeks

Pregnancy-Associated (Granuloma Gravidarum) [8]

• Spontaneous regression post-partum: 50-70% of cases
• Time to regression: 1-3 months post-partum
• Persistence: 30-50% require treatment post-partum
• Recurrence in subsequent pregnancies: ~20%

Satellitosis [7]

• Occurs in 2-5% of cases with inadequate initial treatment
• Presents as multiple small PG lesions (5-50+) around the scar
• Requires wide excision of scar and satellite lesions
• Can be therapeutically challenging (high re-recurrence)

Natural History (Untreated)

• Spontaneous regression: Rare (less than 5%) except in pregnancy
• Persistent lesion: Most remain indefinitely if untreated
• Bleeding episodes: Recurrent, unpredictable
• Quality of life: Significant impact due to bleeding, cosmesis, functional impairment

---

10. Prevention & Screening

Primary Prevention

• Avoid trauma to skin and mucosa (especially in high-risk individuals)
• Good oral hygiene: Reduces gingival PG risk [10]
• Dental care in pregnancy: Regular dental assessment and cleaning; early treatment of gingivitis [8]

Secondary Prevention (Recurrence)

• Thorough cauterisation at initial treatment
• Remove local irritants: Dental calculus, sharp teeth, ill-fitting prostheses (for oral PG)
• Monitor high-risk medications: Consider alternative if multiple PG lesions develop on retinoids/EGFR inhibitors

Screening

Not applicable — pyogenic granuloma is not a condition requiring population screening.

---

11. Key Guidelines & Evidence

Guidelines

British Association of Dermatologists (BAD): Patient information leaflet available; no formal management guideline (reflects benign nature of condition)

National Institute for Health and Care Excellence (NICE): No specific guidance (not a commissioned topic)

American Academy of Dermatology (AAD): No formal guideline; condition covered in general dermatology texts

Evidence Base

The evidence base for pyogenic granuloma management is predominantly observational (case series, retrospective reviews). There are no randomised controlled trials comparing treatment modalities, reflecting the benign nature and straightforward management of the condition.

Key evidence:

• Curettage + cautery: Widely regarded as first-line based on decades of clinical experience and retrospective case series showing 85-90% cure with adequate technique [6]
• Excision: Higher cure rates but increased scarring; reserved for recurrent or atypical lesions [6]
• Laser therapy: Emerging evidence from case series suggests good outcomes with PDL; useful for cosmesis-sensitive areas [19]
• Timolol: Small case series show variable efficacy; promising non-invasive option but not yet established as standard [20]

---

12. Common Exam Questions

Written Exam (SBA/MCQ)

1. "A 7-year-old boy presents with a rapidly growing, bleeding nodule on his finger following a cut 2 weeks ago. What is the most appropriate definitive management?"

   • Answer: Curettage and cauterisation, send for histology

2. "A 28-year-old pregnant woman (28 weeks gestation) develops a gingival lesion that bleeds easily. What is the most appropriate initial management?"

   • Answer: Conservative management with oral hygiene optimisation; reassess post-partum

3. "What is the histological hallmark of pyogenic granuloma?"

   • Answer: Lobular capillary proliferation

4. "Which of the following is the most critical differential diagnosis for pyogenic granuloma?"

   • Answer: Amelanotic melanoma

Viva Voce

Opening Statement:

"Pyogenic granuloma is a common, benign vascular tumour that is histologically termed lobular capillary haemangioma. It presents as a rapidly growing, friable, red nodule that bleeds disproportionately to trauma, typically following minor injury. The name is a misnomer — there is no pyogenic infection or granulomatous inflammation. It occurs in all ages but is particularly common in children, young adults, and pregnant women. The critical differential is amelanotic melanoma, so histological confirmation is mandatory."

Key Facts to Mention:

• Lobular capillary architecture on histology (not pyogenic, not granuloma)
• Common sites: fingers (periungual), face, oral mucosa (especially gingiva in pregnancy)
• First-line treatment: curettage and cauterisation; always send for histology
• Recurrence 10-40% depending on adequacy of cauterisation
• Pregnancy-associated lesions often regress post-partum (50-70%)

Common Viva Questions:

1. "Why is the name 'pyogenic granuloma' a misnomer?"

   • Answer: "The name is historical and inaccurate. 'Pyogenic' implies infection, but there is no infectious aetiology. 'Granuloma' implies granulomatous inflammation, but histology shows lobular capillary proliferation, not granulomas. The accurate term is lobular capillary haemangioma."

2. "What are the risk factors for pyogenic granuloma?"

   • Answer: "The most common precipitant is minor trauma. Other important risk factors include pregnancy (hormonal stimulation of angiogenesis, particularly affecting the gingiva), medications such as retinoids, EGFR inhibitors, and antiretrovirals, and pre-existing vascular lesions like port-wine stains. There is no genetic predisposition."

3. "How would you distinguish pyogenic granuloma from amelanotic melanoma clinically?"

   • Answer: "Clinically they can be indistinguishable, which is why histology is mandatory. However, clues favouring pyogenic granuloma include younger age, history of trauma, rapid growth over days to weeks, profuse bleeding, friable consistency, and a collarette of scale. Amelanotic melanoma is more common in older adults, has firmer consistency, slower growth, and may show irregular borders or subtle pigmentation. Dermoscopy can aid but cannot exclude melanoma."

4. "What is satellitosis and how can it be prevented?"

   • Answer: "Satellitosis is the development of multiple recurrent pyogenic granuloma lesions around the scar of a previously excised lesion. It occurs in 2-5% of cases and is caused by inadequate initial treatment, where residual vascular tissue at the base proliferates. Prevention involves thorough cauterisation of the base at the time of initial treatment, ensuring all vascular tissue is destroyed. If satellitosis occurs, wide excision of the scar and all satellite lesions is required."

---

13. Common Mistakes

❌ Mistake 1: Assuming all friable, red nodules are pyogenic granuloma without histology

• Why it fails: Amelanotic melanoma can be clinically identical. Histology is mandatory to exclude malignancy.
• ✅ Correct approach: Always send specimens for histology, even if clinically confident.

❌ Mistake 2: Inadequate cauterisation of the base after curettage

• Why it fails: Residual vascular tissue at the base leads to recurrence (30-40%) or satellitosis.
• ✅ Correct approach: Thoroughly cauterise the entire base and slightly beyond to destroy feeder vessels.

❌ Mistake 3: Excising pregnancy-associated gingival lesions during pregnancy

• Why it fails: High recurrence during pregnancy due to ongoing hormonal stimulation; many regress post-partum.
• ✅ Correct approach: Conservative management unless symptomatic (bleeding, pain, functional impairment); reassess post-partum.

❌ Mistake 4: Using cryotherapy or silver nitrate as first-line treatment

• Why it fails: High recurrence rates (40-50%+); poor efficacy compared to curettage + cautery.
• ✅ Correct approach: Curettage + cautery as first-line; reserve other modalities for specific scenarios (e.g., laser for facial lesions in children).

❌ Mistake 5: Not checking medication history

• Why it fails: Missing drug-induced PG (retinoids, EGFR inhibitors, TKIs); multiple recurrences likely if medication continued.
• ✅ Correct approach: Always take medication history; consider drug cessation or substitution if implicated.

---

14. Model Answers

Q: "Describe your approach to a patient presenting with a rapidly growing, bleeding nodule on the finger."

Model Answer:

"I would approach this systematically. First, I would take a focused history: onset, duration, rate of growth, any preceding trauma, bleeding episodes, associated symptoms, past medical history, and medications — particularly retinoids, EGFR inhibitors, or antiretrovirals. I would also ask about pregnancy if the patient is female of reproductive age.

On examination, I would look for a friable, red to purple, dome-shaped or pedunculated nodule, assess for a collarette of scale at the base, and note the degree of bleeding with palpation. I would also examine for similar lesions elsewhere (suggesting multiple/eruptive PG).

My differential diagnosis would include pyogenic granuloma as the most likely given rapid growth and bleeding, but critically I must exclude amelanotic melanoma, which can be clinically indistinguishable. Other differentials include Spitz naevus, Kaposi sarcoma, and granulation tissue.

I would consider dermoscopy, which may show red lacunae, white rail lines, and a collarette, but this does not exclude malignancy.

My definitive management would be curettage and cauterisation under local anaesthesia, with thorough cauterisation of the base to reduce recurrence risk. Critically, I would send the specimen for histopathological examination to confirm the diagnosis and exclude melanoma. If there is any diagnostic uncertainty or atypical features, I would proceed directly to excision biopsy.

I would advise the patient on wound care, provide written information, and arrange follow-up to review histology and assess healing. I would warn about a 10-15% recurrence risk and the possibility of satellitosis if the lesion is incompletely treated."

---

Q: "A pregnant woman at 30 weeks' gestation develops a gingival lesion that bleeds when brushing her teeth. How would you manage this?"

Model Answer:

"This is likely granuloma gravidarum — a pregnancy-associated pyogenic granuloma of the gingiva, which occurs in approximately 5% of pregnancies, typically in the second or third trimester. It is driven by hormonal stimulation (oestrogen and progesterone) upregulating VEGF and angiogenesis.

My initial management would be conservative, as 50-70% of these lesions regress spontaneously post-partum. I would reassure the patient, advise excellent oral hygiene, and recommend a dental assessment to remove any local irritants such as calculus or sharp tooth edges, which can exacerbate the lesion.

I would advise soft brushing around the lesion, warm saline rinses, and avoidance of trauma. I would explain that the lesion is benign and hormone-related, and that it will likely resolve after delivery.

However, if the lesion is causing significant bleeding, pain, functional impairment with eating or speaking, or there is secondary infection, I would consider intervention during pregnancy. In this case, I would refer to an oral surgeon for curettage and cauterisation under local anaesthesia, which is safe in pregnancy. I would ensure the specimen is sent for histology to confirm the diagnosis and exclude other pathology.

Post-partum, I would review the patient at 6-8 weeks. If the lesion has not regressed, I would proceed to definitive treatment with surgical excision or curettage and cautery at that time."

---

15. Patient/Layperson Explanation

What is a Pyogenic Granuloma?

A pyogenic granuloma is a small, red, raised lump on the skin or inside the mouth that grows quickly and bleeds very easily. Despite its name, it is not caused by an infection (the name is misleading) — it is a benign (non-cancerous) overgrowth of tiny blood vessels.

What Causes It?

The most common cause is minor injury — a cut, scratch, insect bite, or knock. It can also develop during pregnancy (especially on the gums), or as a side effect of certain medications.

Is It Dangerous?

No, it is not cancer, but it needs to be removed and checked under a microscope (called histology) to make absolutely sure it is not something more serious, like an unusual type of skin cancer (amelanotic melanoma), which can look very similar.

What Are the Symptoms?

• A red, shiny, raspberry-like lump that grows over a few weeks
• Bleeds a lot even with gentle touch (this is the most common reason people seek help)
• Usually painless unless it gets knocked or infected
• Often has a ring of skin around the base (called a collarette)

How is It Treated?

The standard treatment is to scrape it off (curettage) and burn the base (cautery) under local anaesthetic (numbing injection). This is a quick, simple procedure done in a clinic. The removed tissue is then sent to a laboratory to confirm the diagnosis.

Will It Come Back?

Sometimes it can grow back (in about 1 in 10 people), especially if the base was not fully treated. If it does come back, it can be treated again. Rarely, multiple lumps can grow around the scar (called satellitosis) — this needs more extensive removal.

Special Note for Pregnant Women

If you develop a lump on your gums during pregnancy, this is very common (called a "pregnancy tumour" or "granuloma gravidarum"). It often goes away on its own after the baby is born, so unless it is bleeding heavily or causing problems, your doctor may suggest waiting until after delivery before treating it.

When Should I See a Doctor?

See your doctor if you develop a fast-growing, bleeding lump on your skin or in your mouth. It is important to have it checked and removed to confirm it is benign.

---

16. References

1. Patrice SJ, Wiss K, Mulliken JB. Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases. Pediatr Dermatol. 1991;8(4):267-276. PMID: 1792196

2. Mills SE, Cooper PH, Fechner RE. Lobular capillary hemangioma: the underlying lesion of pyogenic granuloma. A study of 73 cases from the oral and nasal mucous membranes. Am J Surg Pathol. 1980;4(5):470-479. PMID: 7435775

3. Lomeli Martinez SM, Carrillo Contreras NG, Gomez Sandoval JR, et al. Oral Pyogenic Granuloma: A Narrative Review. Int J Mol Sci. 2023;24(23):16885. doi:10.3390/ijms242316885

4. Sarwal P, Lapumnuaypol K. Pyogenic Granuloma. StatPearls. Updated 2025. PMID: 32310537

5. Mccormack L, Hawryluk EB. Pediatric melanoma update. G Ital Dermatol Venereol. 2018;153(5):707-715. doi:10.23736/S0392-0488.18.05924-2

6. Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: a review. J Plast Reconstr Aesthet Surg. 2011;64(9):1216-1220. doi:10.1016/j.bjps.2010.12.031

7. Warner J, Jones EW. Pyogenic granuloma recurring with multiple satellites: a report of 11 cases. Br J Dermatol. 1968;80(4):218-227. doi:10.1111/j.1365-2133.1968.tb11969.x

8. Pecci-Lloret MP, Linares-Perez C, Pecci-Lloret MR, et al. Oral Manifestations in Pregnant Women: A Systematic Review. J Clin Med. 2024;13(3):707. doi:10.3390/jcm13030707

9. Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma - the quest for optimum treatment: an audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg. 2007;60(9):1030-1035. doi:10.1016/j.bjps.2007.03.036

10. Jafarzadeh H, Sanatkhani M, Mohtasham N. Oral pyogenic granuloma: a review. J Oral Sci. 2006;48(4):167-175. doi:10.2334/josnusd.48.167

11. Piraccini BM, Bellavista S, Misciali C, et al. Periungual and subungual pyogenic granuloma. Br J Dermatol. 2010;163(5):941-953. doi:10.1111/j.1365-2133.2010.09906.x

12. Alamri A, Alghamdi Y, Alghamdi A, et al. Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma. Cureus. 2022;14(12):e32943. doi:10.7759/cureus.32943

13. Tosti A, Piraccini BM, D'Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol. 1999;140(6):1165-1168. doi:10.1046/j.1365-2133.1999.02895.x

14. Yuan K, Wing LY, Lin MT. Pathogenetic roles of angiogenic factors in pyogenic granulomas in pregnancy are modulated by female sex hormones. J Periodontol. 2002;73(7):701-708. doi:10.1902/jop.2002.73.7.701

15. Greene AK, Goss JA. Vascular Anomalies: From a Clinicohistologic to a Genetic Framework. Plast Reconstr Surg. 2018;141(5):709e-717e. doi:10.1097/PRS.0000000000004294

16. Goh RS, Peh WM, Keng CGH. Pyogenic granuloma gravidarum: A case report. Case Rep Womens Health. 2025;46:e00716. doi:10.1016/j.crwh.2025.e00716

17. Wilson BB, Greer KE, Cooper PH. Eruptive disseminated lobular capillary hemangioma (pyogenic granuloma). J Am Acad Dermatol. 1989;21(2 Pt 2):391-394. doi:10.1016/s0190-9622(89)80042-8

18. Zaballos P, Carulla M, Ozdemir F, et al. Dermoscopy of pyogenic granuloma: a morphological study. Br J Dermatol. 2010;163(6):1229-1237. doi:10.1111/j.1365-2133.2010.10040.x

19. Raulin C, Greve B, Hartschuh W, Hellwig S. Exophytic vascular lesions: pulsed dye laser treatment and histopathological findings. Lasers Surg Med. 1999;25(1):32-41. PMID: 10421059

20. Gupta D, Singh N, Thappa DM. Is timolol an effective treatment for pyogenic granuloma? Int J Dermatol. 2016;55(5):592-595. doi:10.1111/ijd.13237

---